Abstract
Platelet activation plays a pivotal role in the pathogenesis of coronary artery disease. The long-term benefit of dual anti-platelet therapy with clopidogrel and aspirin is well established for patients with acute coronary syndrome and for secondary prophylaxis of coronary artery disease. This review discusses latest developments in the field of the thienopyridines. Particularly, we focus on the evidence-based use of prasugrel or prasugrel versus clopidogrel in clinical practice.
Georg Thieme Verlag KG Stuttgart, New York.
MeSH terms
-
Acute Coronary Syndrome / blood
-
Acute Coronary Syndrome / drug therapy*
-
Administration, Oral
-
Angina, Unstable / blood
-
Angina, Unstable / drug therapy
-
Biological Availability
-
Clopidogrel
-
Coronary Artery Disease / blood
-
Coronary Artery Disease / drug therapy*
-
Humans
-
Metabolic Clearance Rate / physiology
-
Piperazines / adverse effects
-
Piperazines / pharmacokinetics
-
Piperazines / therapeutic use*
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / pharmacokinetics
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Prasugrel Hydrochloride
-
Randomized Controlled Trials as Topic
-
Secondary Prevention
-
Thiophenes / adverse effects
-
Thiophenes / pharmacokinetics
-
Thiophenes / therapeutic use*
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / therapeutic use
Substances
-
Piperazines
-
Platelet Aggregation Inhibitors
-
Thiophenes
-
Clopidogrel
-
Prasugrel Hydrochloride
-
Ticlopidine